Company intelligence / Profile preview

Northern Green Canada

Brampton, Ontario, Canada

Ownership: Private
Employees: ~69
Development stage: Other

Overview

Northern Green Canada supplies pharmaceutical-grade, EU GMP-certified, nonirradiated and irradiated cannabis flowers and extracts for medical use. Acquired by Curaleaf in 2024, NGC’s quality standards and EU-GMP operations have made it a core supplier for international expansion, notably distributing high-THC flower varieties consistently to clinics and wholesalers in several countries.

Therapeutic areas: OtherNeurology
Modalities: Small molecule (cannabinoids, THC/CBD extracts)Biologic (extracts/oils)
Industry: Biotech

Partnerships

Four 20 Pharma GmbH (distribution/supply agreement for Germany and EU)Curaleaf Holdings (parent and global distributor post-acquisition)possibly Peace Naturals

Beyond the preview

Go deeper on Northern Green Canada.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Northern Green Canada.

Explore the full profile